Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis

Journal of the National Cancer Institute

Volumn 91, Issue 10, 1999, Pages 869-874

  Stephens, Ross W ^a   Nielsen, Hans Jørgen ^b   Christensen, Ib J ^a   Thorlacius Ussing, Ole ^c   Sørensen, Steen ^c   Danø, Keld ^a   Brünner, Nils ^a  

^a FINSEN LABORATORY   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033583761     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.10.869     Document Type: Article

References (34)

1. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
2. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-95.
3. Hewitt R, Dano K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein 1996; 49:163-73.
4. Yu HR, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990;50: 7623-33.
5. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996;56:3597-604.
6. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 1992;667: 1-12.
7. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmindependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 1994;158: 398-407.
8. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-37.
9. Skriver L, Nielsen LS, Stephens RW, Dano K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem 1982;124: 409-14.
10. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57: 273-328.
11. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis and Proteolysis 1998;12: 191-204.
12. Stephens RW, Pollanen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989;108: 1987-95.
13. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266:12752-8.
14. Vaheri A, Stephens RW, Salonen EM, Pollanen J, Tapiovaara H. Plasminogen activation at the cell surface-matrix interface. Cell Differ Dev 1990;32:255-62.
15. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-12.
16. Quax PH, Pedersen N, Masucci MT, Weening-Verhoeff EJ, Dano K, Verheijen JH, et al. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991;2:793-803.
17. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13: 3983-91.
18. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993;90: 5021-5.
19. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
20. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994;344:401-2.
21. Grondahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
22. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89:576-81.
23. Pappot H, Hoyer-Hansen G, Ronne E, Hansen HH, Brunner N, Dano K, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997;33:867-72.
24. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43: 1868-76.
25. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
26. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technique on survivor rates. Ann Surg 1967;420-7.
27. Ronne E, Behrendt N, Ploug M, Nielsen HJ, Wollisch E, Weidle U, et al. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 1994;167:91-101.
28. Andersen PK, Vaeth M. Simple parametric and nonparametric models for excess and relative mortality. Biometrics 1989;45:523-35.
29. Source: Table 58, Statistik Årbog 1996. Copenhagen (Denmark): Danmarks Statistik; 1996.
30. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985;55: 1284-90.
31. Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986;58:603-10.
32. Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, et al. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 1998;4:1511-6.
33. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138: 1059-67.
34. Nielsen HJ, Pappot H, Christensen IJ, Brunner N, Thorlacius-Ussing O, Moesgaard F, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer, BMJ 1998; 316:829-30.